Viewing Study NCT02714595

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 1:16 PM
Ignite Modification Date: 2026-02-07 @ 11:41 AM
Study NCT ID: NCT02714595
Status: COMPLETED
Last Update Posted: 2021-01-12
First Post: 2016-02-26
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
Sponsor: Shionogi
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Healthcare-associated Pneumonia (HCAP) View
None Bloodstream Infections (BSI) View
None Hospital Acquired Pneumonia (HAP) View
None Complicated Urinary Tract Infection (cUTI) View
None Sepsis View
None Ventilator Associated Pneumonia (VAP) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None cefiderocol View
None Bloodstream infections (BSI) View
None Complicated urinary tract infection (cUTI) View
None Ventilator associated pneumonia (VAP) View
None Hospital acquired pneumonia (HAP) View
None Sepsis View
None multi-drug resistant pathogens View
None S-649266 View
None Gram-negative pathogens View
None Healthcare-associated pneumonia (HCAP) View
None carbapenem resistant pathogens View